目的：检测人白介素11（interleukin-11, IL-11）基因在弥漫性大B细胞淋巴瘤(diffuse large B-cell lymphoma，DLBCL)患者组织和血清标本中的表达，探讨IL-11 表达与DLBCL患者预后的关系及其对化疗后患者血小板减少的影响。方法：收集2012 年1 月至2016 年12 月于河北省邯郸市第一医院血液科确诊的88 例DLBCL患者和42 例反应性淋巴增生（reactive lymphoid hyperplasia, RLH）患者组织和血液标本。用qPCR方法检测肿瘤组织和血液中IL-11 的表达，应用单因素和多因素Cox 回归分析IL-11 表达与DLBCL患者临床病理特征和预后的关系以及影响患者预后的独立因素，相关性分析DLBCL患者IL-11 表达和化疗后血小板减少的关系，Kaplan-Meier 法分析IL-11 表达与DLBCL患者总生存（OS）时间、无进展生存（PFS）时间的关系。结果：与对照组RLH患者比较，IL-11 在DLBCL患者组织和血液中表达显著升高（组织：7.002±0.357 vs 1.507±0.139；血液：6.700±0.337 vs 1.446± 0.126，均P<0.01）。IL-11 表达与DLBCL患者的肿瘤大小、临床分期、B细胞症状、化疗敏感性及IPI 指数相关(均P<0.01),IL-11 高表达患者OS和PFS较IL-11 低表达患者明显缩短（均P<0.01）。单因素及多因素Cox回归分析显示，IL-11 表达、化疗敏感性和IPI 指数是影响DLBCL 患者预后的独立因素。化疗后血小板减少患者血清IL-11 基因表达与血小板计数呈负相关（r=-0.732, P<0.01)。结论：IL-11 在DLBCL患者组织和血液中高表达，IL-11 高表达DLBCL患者OS和PFS明显缩短，化疗后血小板减少严重。IL-11有望成为DLBCL患者独立的预后评判生物学标志物。

Objective: To detect expression of human interleukin 11 (IL-11) gene in tissue and blood specimens of the patients with diffuse large B-cell lymphoma (DLBCL), and to explore the relationship between expression of IL-11 gene and prognosis of the patients with DLBCL as well as its effect on thrombocytopenia of the patients with DLBCL after chemotherapy. Methods: Tissue and blood specimens of 88 patients with DLBCL and 42 patients with reactive lymphoid hyperplasia (RLH) who were made a definite diagnosis in Department of Hematology, the First Hospital of Handan City of Hebei Province during January 2012 to December 2016 were collected. qPCR was used to detect expression of IL-11 in the tumor tissues and blood specimens. Univariate and multivariate Cox regression analyses were used to analyze relationship of IL-11 expression in the tissues with clinical pathological features and prognosis of the patients with DLBCL as well as independent factors effecting prognosis of the patients. Correlationship between expression of IL-11 and thrombocytopenia after chemotherapy in the patients with DLBCL was analyzed,as wall as relationships of the IL-11 expression with overall survival (OS) and progression free survival (PFS)were analyzed by Kaplan-Meier assay. Results: Comparing with the patients with RLH in control group, expressions of IL-11 in tissue and blood of the patients with DLBCL were significant higher (in tissue: 7.002±0.357 vs 1.507±0.139; in blood: 6.700±0.337 vs 1.446±0.126, all P<0.01). In the patients with DLBCL, expression of IL-11 was correlated to tumor size, clinical staging, B cell symptom, sensitivity of chemotherapy and IPI index (all P<0.01). OS and PFS of the patients with high expression of IL-11 were shorter than those of the patients with low expression of IL-11 (all P<0.01). Expression of IL-11, sensitivity of chemotherapy and IPI index were independent factors affecting prognosis of the patients with DLBCL. In the patients with thrombocytopenia after chemotherapy, expression of IL-11 in serum and platelet count were negative correlated(r=-0.732, P<0.01). Conclusion: IL-11 was highly expressed in tissue and blood of the patients with DLBCL. OS and PFS of the DLBCL patients with high expression of IL-11 were significantly shortened, in whom, platelet severely reduced after chemotherapy. IL-11 might be expected to become an independent biological marker which could judge prognosis of the patients with DLBCL.